Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Convertible Debt (2022 - 2023)

SAB Biotherapeutics' Convertible Debt history spans 2 years, with the latest figure at $541644.0 for Q2 2023.

  • For Q2 2023, Convertible Debt changed N/A year-over-year to $541644.0; the TTM value through Jun 2023 reached $541644.0, changed N/A, while the annual FY2022 figure was $541644.0, N/A changed from the prior year.
  • Convertible Debt reached $541644.0 in Q2 2023 per SABSW's latest filing, roughly flat from $541644.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $541644.0 in Q4 2022 to a low of $541644.0 in Q4 2022.